Double stage activity in aminoglycoside antibiotics

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• Aminoglycoside antibiotics (AGs) are crucial for treating bacterial infections.
• Enzymatic modification by aminoglycoside acetyltransferases (AACs) often leads to antibiotic resistance.
• Understanding AGs' resistance mechanisms is vital for developing new antimicrobial strategies.

Purpose of the Study:

• To investigate the 'double stage activity' of various aminoglycoside antibiotics (AGs).
• To determine which AGs retain antimicrobial activity after enzymatic modification by actinomycete-derived AACs.
• To assess the clinical implications of this retained activity.

Main Methods:

• Testing fourteen different AGs against AACs from actinomycetes.
• Quantifying retained antibiotic activity after enzymatic acetylation.
• Evaluating the sensitivity of Streptomyces lividans TK21 to acetylated AGs.

Main Results:

• Arbekacin (ABK) demonstrated high retained activity after acetylation by AAC(3) and AAC(2').
• Dibekacin (DKB), gentamicin (GM), sisomicin (SISO), netilmicin (NTL), and neomycin (NM) showed varying degrees of retained activity.
• Astromicin (ASTM)-group AGs lost all activity after acetylation.
• Bacterial sensitivity correlated with the AGs' 'double stage activity'.

Conclusions:

• 'Double stage activity' is a significant factor in aminoglycoside antibiotic efficacy and resistance.
• Arbekacin shows promising potential due to its high retained activity.
• Further research into AGs with 'double stage activity' could lead to novel therapeutic agents.